NO20030328D0 - 3-Indolyl-4-fenyl-1H-pyrrol-2,5-dion-derivater som inhibitorer av glykogen-syntase-kinase-3beta - Google Patents

3-Indolyl-4-fenyl-1H-pyrrol-2,5-dion-derivater som inhibitorer av glykogen-syntase-kinase-3beta

Info

Publication number
NO20030328D0
NO20030328D0 NO20030328A NO20030328A NO20030328D0 NO 20030328 D0 NO20030328 D0 NO 20030328D0 NO 20030328 A NO20030328 A NO 20030328A NO 20030328 A NO20030328 A NO 20030328A NO 20030328 D0 NO20030328 D0 NO 20030328D0
Authority
NO
Norway
Prior art keywords
3beta
indolyl
pyrrole
inhibitors
phenyl
Prior art date
Application number
NO20030328A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030328L (no
Inventor
Leyi Gong
Andrew Grupe
Gary Allen Peltz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20030328L publication Critical patent/NO20030328L/no
Publication of NO20030328D0 publication Critical patent/NO20030328D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20030328A 2000-07-27 2003-01-22 3-Indolyl-4-fenyl-1H-pyrrol-2,5-dion-derivater som inhibitorer av glykogen-syntase-kinase-3beta NO20030328D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27
PCT/EP2001/008293 WO2002010158A2 (en) 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta

Publications (2)

Publication Number Publication Date
NO20030328L NO20030328L (no) 2003-01-22
NO20030328D0 true NO20030328D0 (no) 2003-01-22

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030328A NO20030328D0 (no) 2000-07-27 2003-01-22 3-Indolyl-4-fenyl-1H-pyrrol-2,5-dion-derivater som inhibitorer av glykogen-syntase-kinase-3beta

Country Status (32)

Country Link
US (2) US6479490B2 (ru)
EP (1) EP1307447B1 (ru)
JP (1) JP3984157B2 (ru)
KR (1) KR20030017655A (ru)
CN (1) CN1185229C (ru)
AR (1) AR033989A1 (ru)
AT (1) ATE284885T1 (ru)
AU (1) AU2001293702A1 (ru)
BR (1) BR0112965A (ru)
CA (1) CA2417277A1 (ru)
CZ (1) CZ2003555A3 (ru)
DE (1) DE60107857T2 (ru)
EC (1) ECSP034452A (ru)
ES (1) ES2233691T3 (ru)
GT (1) GT200100151A (ru)
HK (1) HK1058670A1 (ru)
HR (1) HRP20030030A2 (ru)
HU (1) HUP0301431A2 (ru)
IL (1) IL153851A0 (ru)
JO (1) JO2293B1 (ru)
MA (1) MA26936A1 (ru)
MX (1) MXPA03000695A (ru)
NO (1) NO20030328D0 (ru)
NZ (1) NZ523462A (ru)
PA (1) PA8523001A1 (ru)
PE (1) PE20020338A1 (ru)
PL (1) PL366701A1 (ru)
RU (1) RU2003104796A (ru)
UY (1) UY26857A1 (ru)
WO (1) WO2002010158A2 (ru)
YU (1) YU4403A (ru)
ZA (1) ZA200300216B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
EA200300442A1 (ru) * 2000-10-02 2003-10-30 Редди Ю Эс Терапьютикс, Инк. Способы и композиции для лечения воспалительных заболеваний
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
NZ525656A (en) * 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
CA2461144A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
WO2003057202A1 (en) * 2002-01-10 2003-07-17 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
PT1483265E (pt) 2002-03-05 2007-01-31 Lilly Co Eli Derivados de purina como inibidores de quinase
AU2003217596A1 (en) 2002-03-08 2003-09-22 Eli Lilly And Company Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
TWI324064B (en) * 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
AU2003240517A1 (en) * 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
JP2005531609A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
JP2007509185A (ja) * 2003-10-27 2007-04-12 ノバルティス アクチエンゲゼルシャフト βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
US20100152044A1 (en) * 2004-05-12 2010-06-17 Bayer Cropscience Gmbh Plant growth regulation
JP5289769B2 (ja) 2004-12-08 2013-09-11 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ ３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
JP4747364B2 (ja) 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
US8071595B2 (en) * 2008-06-25 2011-12-06 Envivo Pharmaceuticals, Inc. 1,2-disubstituted heterocyclic compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
BR112013005689A2 (pt) * 2010-09-08 2016-05-03 Sumitomo Chemical Co método para produção de compostos de piridazinona e intermediário dos mesmos
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458A (zh) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
JP2000502097A (ja) 1995-12-20 2000-02-22 メディカル、リサーチ、カウンシル タンパク質合成の制御、および作用薬のスクリーニング法
EP1019043A4 (en) 1996-05-07 2003-07-30 Univ Pennsylvania GLYCOGENE SYNTHETASE KINASE-3 INHIBITORS AND METHODS OF IDENTIFYING AND USING THOSE INHIBITORS
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
PL366701A1 (en) 2005-02-07
ATE284885T1 (de) 2005-01-15
HK1058670A1 (en) 2004-05-28
NO20030328L (no) 2003-01-22
EP1307447A2 (en) 2003-05-07
CN1444581A (zh) 2003-09-24
US20020188018A1 (en) 2002-12-12
AR033989A1 (es) 2004-01-21
PE20020338A1 (es) 2002-04-23
JP3984157B2 (ja) 2007-10-03
UY26857A1 (es) 2002-01-31
EP1307447B1 (en) 2004-12-15
GT200100151A (es) 2002-05-23
YU4403A (sh) 2006-05-25
MXPA03000695A (es) 2003-06-04
WO2002010158A3 (en) 2002-05-16
DE60107857T2 (de) 2005-12-08
JO2293B1 (en) 2005-09-12
CZ2003555A3 (en) 2004-03-17
JP2004505078A (ja) 2004-02-19
CN1185229C (zh) 2005-01-19
US20020052397A1 (en) 2002-05-02
HUP0301431A2 (hu) 2003-08-28
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
IL153851A0 (en) 2003-07-31
MA26936A1 (fr) 2004-12-20
AU2001293702A1 (en) 2002-02-13
BR0112965A (pt) 2003-07-08
US6479490B2 (en) 2002-11-12
DE60107857D1 (de) 2005-01-20
ECSP034452A (es) 2003-03-10
PA8523001A1 (es) 2002-10-24
ES2233691T3 (es) 2005-06-16
KR20030017655A (ko) 2003-03-03
ZA200300216B (en) 2004-04-08
CA2417277A1 (en) 2002-02-07
HRP20030030A2 (en) 2005-02-28
WO2002010158A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
NO20030328L (no) 3-Indolyl-4-fenyl-1H-pyrrol-2,5-dion-derivater som inhibitorer av glykogen-syntase-kinase-3beta
NO20053546D0 (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroiddehydrogenase-1.
NO20055565D0 (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
DK1185529T3 (da) Pyrazolbenzodiazepiner som CDK2-inhibitorer
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
NO20020377L (no) Podede polymerer som gasshydratinhibitorer
NO20032034L (no) Indolylmaleimidderivater som proteinkinase C-inhibitorer
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1650203T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
NO20052595D0 (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
PT1296981E (pt) Derivados substituidos da pirrolopiridinona uteis como inibidores da fosfodiesterase
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1178986T3 (da) Furanonderivater som inhibitorer af cathepsin S
NO20031838L (no) Benzoksazinonderivater, deres fremstilling av anvendelse
FI20002903A0 (fi) Bittinopeuden määrittäminen
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application